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Abstract. 
Background: Radiofrequency ablation (RFA) has been regarded as an effective treatment for 
early and small hepatocellular carcinoma (HCC). In vivo porcine studies showed a multiple- 
electrode switching system could create larger necrotic areas than single-electrode or cluster- 
electrode ablations. Some recent studies demonstrated a multiple-electrode RFA system could 
achieve local control of medium-sized HCCs. This study aimed to evaluate the treatment re-
sults of monopolar RFA with either single-electrode overlapping ablations or a multiple- 
electrode switching system in treating medium-sized (3-5 cm) HCC. 
Methods: A total of 20 patients with medium-sized hepatocellular carcinomas were included 
in this study. Nine patients (6 males and 3 females) were treated with single- electrode mono-
polar RFA. Eleven patients (4 males and 7 females) were treated with multiple- electrode 
switching monopolar RFA. Twelve patients (60%) included in this study had multi- nodular 
HCCs at the time of treatment. The tumor size was slightly larger in the multiple- electrode 
group (4.6 ± 0.3 cm) compared to that in the single-electrode group (3.6 ± 0.6 cm). CT or MR 
imaging studies were performed at 1 month after RFA to evaluate treatment effectiveness. 
Thereafter, local tumor progression, treatment effectiveness and survival after RFA were 
evaluated. 
Results: Overall, 18 of 20 patients (90%) showed satisfactory ablation of HCCs 1 month after 
their RFA procedures. Treatment effectiveness was achieved in 8 patients (88.9%) with single- 
electrode overlapping ablation and 10 (90.9%) patients with multiple-electrode switching sys-
tem. The mean follow-up periods were 14.9 (range, 2-26) months in the single-electrode 
group, and 20.2 (range 4-41) months in the multiple-electrode group. Among the 18 patients 
who achieved primary tumor control, 2 patients (1 in the single-electrode group and 1 in the 
multiple-electrode group) had local progression noted during follow-up examinations. 
Conclusions: Medium-sized hepatocellular carcinoma can be effectively ablated with mono-
polar radiofrequency ablation by either single-electrode overlapping ablation or a multiple- 
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electrode switching system. Regarding mid-term treatment responses, both RFA approaches 
can achieve similar treatment effectiveness, local tumor progression rate, and survival proba-
bilities. Multiple-electrode switching RFA can treat larger medium-sized HCC with compara-
ble mid-term efficacy as smaller medium-sized HCC treated with single-electrode overlapping 
RFA. 
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中文摘要 
背景：射頻消融術在治療早期小型肝細胞癌俱有相當好的療效。動物實驗發現多針電極
切換系統能夠產生較傳統單針電極或集束電極系統消融更大的體積。最近有些研究使用
多針電極射頻消融術證實能達到局部控制中型肝細胞癌。本研究的目的在評估單極射頻
消融術使用單針重疊消融或多針切換系統治療 3 至 5 公分大小的中型肝細胞癌的治療成
效。 
方法：本研究共收入 20 位中型肝細胞癌的患者。9 位患者(6 位男性與 3 位女性)接受單針
重疊單極射頻消融術。11 位患者(4 位男性與 7 位女性)接受單針單極多針切換系統射頻消
融術。本研究收入的患者中，有 12 位(60%)患者在接受治療時肝細胞癌為多發結節。多
針切換系統治療患者的腫瘤大小(4.6 ± 0.3 公分)較單針重疊消融(3.6 ± 0.6 公分)為大。接受
治療一個月後以電腦斷層或核磁共振評估治療成效。本研究評估患者接受射頻消融術後
之治療成效、局部腫瘤復發、總和存活。 
結果：總和來說，18 位(90%)中型肝細胞癌患者接受射頻消融術後一個月評估達到腫瘤完
全消融。細分來說，8 位患者(88.9%)接受單針重疊單極射頻消融術達完全消融，10 位患
者(90.9%)接受單針單極多針切換系統射頻消融術達完全消融。接受單針重疊單極射頻消
融術患者之平均追蹤時間為 14.9 個月(總範圍 2 至 26 個月)，而接受單極多針切換系統射
頻消融術為 20.2 個月(總範圍 4 至 41 個月)。在 18 位達到腫瘤完全消融的患者，2 位患者
(一位接受單針重疊消融，另一位接受多針切換系統消融)在追蹤期間有局部腫瘤復發。 
結論：中型肝細胞癌可以有效地使用單極射頻消融術治療，在本中期追蹤研究中顯示，
不論是使用單針重疊消融或是多針切換系統消融皆能夠達到類似的腫瘤完全消融率、局
部腫瘤復發率、與總和存活率。多針切換系統治療較大的中型肝細胞癌與單針重疊術式
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消融較小的中型肝細胞癌的治療效果相當。 
 
關鍵字: 單極射頻消融、單針重疊消融、多針切換系統、熱消融 
 
INTRODUCTION 
Radiofrequency ablation (RFA) can effectively 
treat hepatocellular carcinoma (HCC) smaller than 2 
cm [1,2]. Ablation, resection, and transplantation were 
considered as effective treatments for early-stage HCC 
[3]. Local ablation was suggested as first-line treat-
ment for HCC less than 3 cm in size [3]. Among local 
ablation therapies, RFA was one of the most com-
monly applied treatment because of its low probability 
of local recurrence and favorable long-term outcomes 
[4]. RFA was suggested by prospective randomized 
studies to have comparable outcome to surgical resec-
tion treating single small HCC [1]. Therefore, RFA 
was recommended as one of the curative treatments 
for early-stage HCC [2]. 
RFA was less effective against medium and large 
HCCs [5]. By using a single electrode for HCC be-
tween 3 to 4 cm and a triple electrode cluster placed 5 
mm apart for HCC larger than 4 cm, RFA can achieve 
complete ablation in 61% of medium-sized HCC and 
only 24% in large-sized HCC [5]. A computational 
analysis suggested that overlapping multiple ablation 
was required by single-electrode RFA to achieve sat-
isfactory ablation [6]. In vivo porcine studies testing a 
prototype of multiple-electrode switching system 
(ValleyLab) could create larger necrotic areas than 
single-electrode or cluster-electrode ablations [7]. 
Some recent studies demonstrated a multiple-electrode 
RFA system could achieve local control of medi-
um-sized HCCs between 3 and 5 cm [8]. However, the 
effects of monopolar single-electrode system with 
multiple sequential ablation in managing intermediate 
sized HCCs have remained unclear. 
The effectiveness of RFA in treating medium- 
sized HCCs remains controversial and has been min-
imally reported. The purpose of this study was to in-
vestigate the technique effectiveness of the monopolar 
RFA system using single-electrode or a multiple- 
electrode switching control system in treating inter-
mediate sized HCC. The technique effectiveness and 
outcome of treatment were compared between the 
monopolar single-electrode system and the monopolar 
multiple-electrode switching control system. 
 
MATERIALS AND METHODS 
 
Patients 
From Dec. 2009 to Dec. 2013, patients who re-
ceived RFA procedures for hepatocellular carcinomas 
were retrospectively evaluated and included into this 
study using the following criteria: (1) the malignan-
cies were diagnosed by pathological studies, or HCC 
fulfilled the criteria of the guidelines of the American 
Association for the Study of Liver Diseases published 
in 2010 (typical vascular pattern in computed tomog-
raphy scan or magnetic resonance imaging study) [2], 
(2) diameter of the largest tumor size between 3 cm to 
5 cm, (3) platelet count was more than 40,000/mm3, 
(4) Child-Pugh class A or B, and (5) no radiographic 
evidence of HCC invading major vessels including the 
main portal vein or hepatic veins. 
 
Radiofrequency Ablation 
The single electrode RFA procedure was per-
formed as followed: an internally cooled 17-gauge 
monopolar radiofrequency electrode (Valleylab) with 
an electrically active tip was placed by percutaneous 
punctures through the intercostal space or upper ab-
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domen to the liver. The electrode was inserted using 
the freehand technique under real-time sonographic 
guidance by a 1-5 MHz convex probe (C5-1, Philips) 
in conjunction with a iU22 ultrasound system (Philips). 
The radiofrequency energy was delivered to each 
electrode with a 480-kHz power generator (Series 
CC-1, Valleylab) with a maximum power of 200 watts. 
Energy output from the power generator was regulated 
using a feedback algorithm related to tissue imped-
ance. The electrode was subsequently re-inserted by 
freehand puncture to pre-procedurally planned posi-
tions, 1 to 2 cm distant from each of the ablation tracts. 
The immediate response was assessed by the presence 
of a hyperechoic rim beyond the border of target tu-
mors to be ablated the electrode was reinserted and 
re-ablation was performed at the location around the 
tumor with incomplete hyperechoic rim. 
The multiple-electrode switching control system 
RFA procedure was performed as followed: Two or 
three internally cooled 17-gauge monopolar radiofre-
quency electrodes (Valleylab) with an electrically ac-
tive tip were placed percutaneously by freehand 
punctures through the intercostal space or upper ab-
domen to the target ablation area comprising HCCs. 
The distances between the electrically active tips of 
electrodes were 1 to 2 cm. The procedures were per-
formed using the same ultrasound system mentioned 
in previous sections (the probe was C5-1, Philips, and 
the ultrasound system used was the iU22, Philips).  
The switching control system power generator was the 
same as the one used in the single ablation system. 
The power generator was capable of delivering a 
maximum power of 200 watts in 480-kHz (Series 
CC-1, Valleylab). An additional switching control 
generator was used to alternate the ablation between 
either duo or triple electrodes (Valleylab). Only one 
electrode was utilized to deliver RF energy into the 
target tissue at the same time. The ablation was per-
formed in the following order: the first phase of abla-
tion was performed using maximum power regulated 
by a feedback algorithm based on tissue impedance 
for 3 minutes to each electrode sequentially. The se-
cond phase of ablation was performed using the 
switching system such that radiofrequency energy was 
delivered to each electrode for 30 seconds unless the 
tissue impedance had abruptly risen when the energy 
delivery was switched to the next electrode. We as-
sessed response to ablation based upon the presence of 
a hyperechoic rim as previously described. Additional 
ablations were performed at locations with incomplete 
hyperechoic rim around the tumors. 
A single operator performed all of the RFA pro-
cedures in this study. The electrodes used in the sin-
gle-electrode or multiple-electrode switching control 
Table 1. Characteristics of patients and tumors at the baseline of RFA treatment 
 Single-electrode (n=9) Switching system (n=11) P-value 
Age (year) 60.4 ± 16.5 (42.5-81.7) 70.3 ± 9.4 (59.5-89.8) 0.201 
Gender (M/F)    
 Male 6 4 0.370 
 Female 3 7  
Liver cirrhosis    
 Child-Pugh class (A/B) 5/4 8/3 0.642 
Multinodularity 5 (55.6%) 7/11 (63.6%) 1.000 
Size of largest tumor (cm) 3.6 ± 0.6 (3.1-4.5) 4.6 ± 0.3 (3.9-5.0) 0.020 
Follow-up since RFA (mo) 14.9 ± 9.8 (2-26) 20.2 ± 12.0 (4-41) 0.261 
Note. Data presented with plus–minus values are means ± SD. HCC: hepatocellular carcinoma; RFA: radiofrequency ablation 
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system had inflow and outflow connectors for contin-
uous circulation of chilled distilled water maintained 
by a system pump (model PEPM, Valleylab) to keep 
the temperature of the active tip of the electrode with-
in 0-10°C. Tract ablation was performed at the end of 
the procedure to remove the electrodes. Intravenous 
sedation was induced with meperidine in addition to 
midazolam, or an anesthesiologist performed intrave-
nous general anesthesia. Neither endotracheal intuba-
tion nor mechanical ventilation was required in this 
study. The subject’s vital signs, electrocardiogram, 
and oxygen saturation were monitored during the RFA 
procedure. 
 
Evaluation of Treatment Response and 
Follow-up 
One month after the procedure, alpha-fetoprotein 
and liver biochemistries were evaluated. A multi- 
phase CT or MR imaging (unenhanced, arterial, portal, 
and venous phases) was performed to evaluate the 
primary technique effectiveness. Non-enhanced area 
in portal phase was considered as the necrosis zone. 
Complete ablation was defined as the necrosis zone 
incorporating the target tumors. The patients were 
then regularly followed up every 3 months. Arterial 
enhancing soft tissue densities or signals around the 
margin of the necrosis zone related to treatment were 
defined as local tumor progression. Newly developed 
intra-hepatic soft tissue densities or signals with radi-
ographic features of HCC but remote to treated nod-
ules were defined as remote recurrence. 
 
Statistical Analysis 
Patient age, numbers and sizes of tumors, and total 
ablation time were compared between the treatment 
sessions with and without recurrence after RFA using 
the Wilcoxon rank sum test. Gender, multi-nodularity 
of HCC, and treatment effectiveness at 1 month were 
evaluated using Fisher’s exact test. The cumulative 
survival rate and local progression rate were analyzed 
using the Kaplan-Meier method. The difference of the 
survival and local progression rate between single- 
electrode overlapping ablation and multiple-electrode 
switching system was assessed with the log-rank test. 
All statistical analyses described were performed us-
ing the IBM SPSS Statistics for Windows, Version 
20.0. Statistical significance was defined at a two- 
tailed probability value of less than 0.05 in all anal-
yses. 
 
RESULTS 
 
Patient Characteristics 
There was a total of 20 patients (10 male and 10 
female) included in this study. Nine patients (6 males 
and 3 females) were treated with single-electrode 
monopolar RFA. Eleven patients (4 males and 7 fe-
males) were treated with multiple-electrode switching 
monopolar RFA. The age of patients at baseline 
ranged from 42.5 to 89.8 years (mean 65.9). Patients  
Table 2. Characteristics and outcomes of RFA treatment 
 Single-electrode (n=9) Switching system (n=11) P-value 
Ablation time (minutes) 48.6 ± 27.6 (18-87) 59.4 ± 18.5 (27-95) 0.295 
Effectiveness at 1 month 88.9% (8 of 9) 90.9% (10 of 11) 1.000 
Local progression1 1 of 8 1 of 10 1.000 
Rapid tumor progression 12 13 1.000 
Note. 1. Patients who achieved RFA effectiveness at 1 month were included 
2. This patient had local tumor progression and distant metastasis 
3. This patient had distant metastasis 
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Figure 1. Cumulative incidence of local tumor progression: (A) all patients in this study, and (B) two individual 
groups of RFA approaches (solid line: all patients, dotted line: single-electrode overlapping ablation, 
dashed line: multiple-electrode switching system) 
 
 
in the multiple-electrode group were slightly but not 
significantly older than those in the single-electrode 
group (60.4 ± 16.5 vs 70.3 ± 9.4). Five patients in the 
single-electrode group belonged to Child-Pugh class 
A and 4 patients belonged to Child-Pugh class B. 
Within the multiple-electrode group, 7 patients were 
designated Child-Pugh class A, and 4 patients were 
designated Child-Pugh class B. Twelve patients had 
multi-nodular HCCs at the time of RFA treatment (5 
in single-electrode, 7 in multiple-electrode). The tu-
mor size was larger in the multiple-electrode group 
(mean 4.6 cm, standard deviation 0.3 cm) comparing 
to that in the single-electrode group (mean 3.6 cm, 
standard deviation 0.6 cm) (Table 1). 
 
RFA Treatment and Effectiveness of 
Treatment 
CT or MR imaging studies were performed 1 
month after RFA to evaluate treatment effectiveness, 
which was defined as complete necrosis of target ab-
lation tumor. Among the 20 patients, treatment effec-
tiveness was achieved in 18 patients (90%) at 1 month. 
For patients where different approaches were used, 8 
patients (88.9%) in single-electrode group and 10 
(90.9%) patients had effective treatment. 
One patient that belonged to the multiple-electrode 
group in this study had a bile duct injury with biloma 
and required drainage. One patient with local progres-
sion in the single-electrode group received 2 follow- 
up RFA interventions to treat locally progressed HCC. 
However, the deterioration of liver reserve including 
intractable ascites and aggravated coagulopathy lim-
ited the effectiveness of the follow-up RFA proce-
dures and caused intraperitoneal hemorrhage and re-
gional peritoneal tumor seeding. No immediate or 
periprocedural mortality was associated with RFA in 
this study. 
Rapid tumor progression was observed in 2 pa-
tients. These patients were found to have HCC sys-
temic metastases within 1 month after the procedure. 
One patient’s outcome in the single-electrode group 
who did not achieve treatment effectiveness suggested 
that 1 of 3 target tumors had rapid local progression, 
portal vein thrombosis, and metastasis to bone and 
brain within one month after treatment. One patient in 
the multiple-electrode group showed metastasis to the 
lymph nodes within 3 weeks after treatment and sub-
sequent brain and spinal metastasis despite complete  
A B
S. Y. Wang et al./JCRP 2(2015) 12-21 17
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Overall survival of (A) all patients in this study, and (B) two individual groups of RFA approaches (solid 
line: all patients, dotted line: single-electrode overlapping ablation, dashed line: multiple-electrode 
switching system). 
 
 
necrosis of the 4 targeted HCCs. This patient received 
RFA for recurrent HCCs, which occurred only 3 
months after primary resection of HCC. Pathological 
studies for the initial HCC specimen revealed micro-
scopic vascular invasion that is reported to be associ-
ated with early recurrence and poor prognosis [9]. 
 
Local Tumor Progression and Survival 
The mean follow-up period after ablation for HCC 
was 17.8 (range from 2 to 41) months. The mean  
follow-up periods were 14.9 (range, 2-26) months in 
the single-electrode group, and 20.2 (range 4-41) 
months in the multiple-electrode group. Among the 18 
patients who achieved primary local tumor control, 
one patient in the single-electrode group had local 
progression 6 months after the first treatment and one 
patient in the multiple-electrode group had local pro-
gression 10 months from the initial RFA treatment. 
Figure 1 showed the cumulative incidence of local 
tumor progression after initial RFA treatment in all 
patients and corresponding RFA treatment groups.  
Overall, a total of 6 patients died during follow-up. 
The cause of death in all of these patients was related 
to liver cancer. Two patients died of rapid tumor pro-
gression, one patient died of local tumor progression, 
one patient had local progression controlled but died 
of intrahepatic remote recurrence, and two patients 
died of intrahepatic remote recurrence. The overall 
cumulative probabilities of survival at 1-year and 
2-year were 77% and 63%, respectively. The proba-
bilities of survival in the single-electrode and multi-
ple-electrode group at 1-year were 73% and 81%, re-
spectively. Figure 2 showed the overall survival after 
initial RFA treatment. 
 
DISCUSSION 
Medium-sized HCC can be effectively ablated us-
ing either the single-electrode overlapping ablation or 
the multiple-electrode switching system. Monopolar 
single-electrode RFA overlapping ablation achieved 
88.9% (8 of 9) complete ablation of the target HCC, 
whereas the multiple-electrode switching system 
achieved 90.9 % (10 of 11) complete ablation. Overall, 
monopolar RFA achieved 90% effectiveness in treat-
ing medium-sized HCC. The local progression rates in 
the single-electrode and multiple-electrode groups at 
1-year were 17% and 12%, respectively. The probabil-
ities of survival in the single-electrode and multiple- 
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electrode groups at 1-year was 73% and 81%, respec-
tively. 
A single radiofrequency ablation with a single in-
ternally cooled electrode was not satisfactory for 
treating medium-sized HCC. Livraghi et al. reported 
that RFA induced 61% complete necrosis rate for 3 to 
4 cm HCC with a single electrode in one ablation, 4 to 
5 cm HCC with a triple electrode cluster in one abla-
tion or a single electrode in 2 to 4 ablations [5]. Re-
garding the expandable electrode RFA system, com-
plete necrosis was observed in 93.0 to 97.8% in ablat-
ing HCC less than 3 cm [10,11]. RFA with an ex-
pandable electrode was less effective against medi-
um-sized HCC, in which the complete necrosis rate 
was 64.7% [11]. Overlapping RFA alone with a single 
internally cooled electrode was reported to reach 94% 
technique effectiveness in ablating medium-sized 
HCC [12]. Insertion of a single electrode was gener-
ally not unduly demanding even in patients with a 
small window allowed for needle pass. However,  
single-electrode overlapping ablation would be diffi-
cult to perform due to the presence of microbubbles 
from preceding ablations which obscured the path for 
placing the electrode in subsequent target positions. 
Multiple-electrode switching RFA showed favora-
ble short-term and mid-term outcomes in treating  
medium-sized HCC [4,8,13]. The major advantage of 
this system was reported to be the creation of a larger 
necrosis volume than either the single-electrode or 
multiple-electrode cluster RFA [7]. Thus, a wider  
tumor-free margin can be theoretically achieved. Pre-
vious RFA studies of small HCC suggested that   
tumor-free margin was related to local tumor progres-
sion [14]. In fact, the local tumor progression rate of 
medium-sized HCC treated by multiple-electrode 
switching RFA was lower than that rate reported in 
previous studies with single-electrode multiple abla-
tions [13]. Without ultrasound artifacts related to pre-
ceding ablations, the placement of electrodes in the 
switching system can be placed in more desirable lo-
cations. However, the insertion of multiple needles 
can be challenging especially in patients with narrow 
intercostal spaces. The treatment time required by 
switching RFA system was reported to be shorter than 
that of single-electrode overlapping ablation [15]. 
Time savings can be significant as a dozen ablations 
may be required for a single-electrode system to ablate 
substantially larger tumors [6]. 
Rapid growth of residual HCCs or early diffuse 
recurrence after RFA was uncommon [16,17]. Ill-  
defined tumor margin and large-size HCC were sug-
gested as risk factors for early diffuse HCC recurrence 
[16]. This intrahepatic recurrence pattern was associ-
ated with poor prognosis [17]. Rapid tumor progres-
sion observed in our study was defined as multiple 
intrahepatic or systemic metastases within 1 month 
after RFA. The 2 patients with rapid tumor progres-
sion after RFA had more ominous courses and had 
survived only 2 and 4 months after RFA, respectively. 
In vitro studies mimicking suboptimal RFA with heat 
treatment found that the residual tumors had enhanced 
tumor growth and angiogenesis through HIF-1a/ 
VEGFA pathway [18]. Epithelial-mesenchymal tran-
sition (EMT), a process related to cancer invasion or 
metastasis, was promoted in HCC cell lines after sub-
lethal heat treatment [19]. These in vitro studies sug-
gested that heat treatment might promote the growth 
and metastasis of HCC. These studies may imply po-
tential mechanisms for the rapid tumor progression 
observed in our study. One hypothesis is that those 
recurrent or metastatic HCCs may have earlier existed 
as microscopic metastasis undetectable by preproce-
dural studies and RFA promotes the growth of those 
microscopic metastasis despite complete ablation of 
the target tumors. Another hypothesis is that RFA ab-
lated the tumor incompletely and the residual tumor 
cells may exert elevated malignant potential and me-
tastasis. 
 The current study was limited by several factors. 
First, the patient number was small and the study de-
sign was retrospective. The selection of RFA treat-
ment with either single-electrode overlapping ablation 
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or multiple-electrode switching system was not ran-
domized. Second, the patient population was hetero-
geneous. Half of the patients (10 of 20, 50%) had pri-
or HCC treatments in diversified modalities. One pa-
tient of the single-electrode group received intrave-
nous sedation due to patient preference, whereas the 
others in this study received intravenous general an-
esthesia. Finally, the lack of ultrasound contrast lim-
ited the immediate real-time evaluation of ablation 
zones after RFA procedures. We used the develop-
ment of a hyperechoic rim around the HCC under 
conventional ultrasound to guide our ablations. In vi-
vo porcine studies using an expandable electrode sug-
gested that the presence of hyperechoic rim was relat-
ed to complete necrosis of liver tissue [20]. RFA in 
HCC patients with an internally cooled electrode 
(Cool-Tip) or expandable electrode showed that the 
hyperechoic rim correlated well with perfusion defects 
detected on contrast-enhanced ultrasound and on fused 
images from contrast-enhanced CT and ultrasound 
performed 3-4 days after RFA [20]. 
In summary, medium-sized hepatocellular carci-
noma can be effectively ablated with monopolar ra-
diofrequency ablation by using either the single-  
electrode overlapping ablation or a multiple-electrode 
switching system. Regarding mid-term treatment re-
sponses, both RFA approaches can achieve similar 
treatment effectiveness, local tumor progression rate, 
and survival probabilities. Multiple-electrode switch-
ing RFA can treat larger medium-sized HCC with 
comparable mid-term efficacy as smaller medi-
um-sized HCC treated with single-electrode overlap-
ping RFA. 
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